Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

that resulted primarily from European market development efforts related to the Company's APTIMA HPV and PROGENSATM PCA3 assays.

General and administrative (G&A) expenses in the first quarter of 2008 were $11.9 million, compared to $11.3 million in the prior year period, an increase of 5% that resulted primarily from higher legal costs.

Gen-Probe continues to have a strong balance sheet. As of March 31, 2008, the Company had $487.6 million of cash, cash equivalents and short-term investments, and no debt. In the first quarter of 2008, Gen-Probe generated net cash of $67.5 million from its operating activities, more than double net income of $31.9 million.

Updated 2008 Financial Guidance

"We believe our strong operating performance in the first quarter has us off to a good start in 2008, and we are therefore raising our full-year revenue and EPS guidance," said Herm Rosenman, the Company's senior vice president of finance and chief financial officer.

For the full year 2008, Gen-Probe now expects:

-- Total revenues of $450 million to $455 million.

-- Product gross margins approximating 68% to 70% of product sales.

-- R&D expenses approximating 23% to 24% of total revenues. The Company

expects quarterly R&D expenses to average more than $27 million for

the rest of 2008, with much of the increase associated with the US

clinical trial of the APTIMA HPV assay.

-- Marketing and sales expenses approximating 9% to 10% of total

revenues.

-- G&A expenses approximating 11% of total revenues.

-- EPS of between $1.72 and $1.76, based on 55 million to 56 million

fully diluted shares outstanding for the year and a tax rate of

34% to 35%.

Recent Events

-- Regulatory Application for PROCLEIX ULTRIO Assay Submitted. On

February 21, Gen-Probe announced that the Company had submitted to the

U.S.
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... British Columbia and MENLO ... --  DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar ... developing and commercializing proven cancer therapies in new ... at the 106th Annual Meeting of the ... Meeting on the potential for its lead product ...
(Date:4/20/2015)... 2015 Orthobiologics are substances that ... The orthobiologics market is a rewarding market, which represents ... global orthobiologics market report defines and segments the concerned ... orthobiologics market was valued at $5,712.4 million in 2014, ... at a CAGR of 6.7% from 2014 to 2019. ...
(Date:4/20/2015)... PointCross Life Sciences today announced a strategic ... Big Data and globally accessible environment for genomic interpretation ... of clinical trials and nonclinical studies. This platform will ... stratified patient selection and ex post analysis ... Highlighting the timing of this partnership, Dr. ...
(Date:4/20/2015)... -- "Everybody is affected by cancer sooner or later," Dr. ... We,ve got to get away from that."  If you,ve ... loved one or friend battling for their life against ... other treatments cause the human body. It,s almost enough ... succumb to the disease. Dr. Dionne has developed a ...
Breaking Biology Technology:DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3PointCross Life Sciences and InterpretOmics partner for Clinical and Genomic Biomarker Management for Drug Development 2Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... Leading medical malpractice insurance company, Healthcare Providers Insurance ... its New Jersey operations.  The company has opened a ... to continue servicing the medical community in New Jersey. ... in New Jersey since 2005.   ...
... AUSTIN, Texas, Aug. 1, 2011 Vermillion, Inc. (NASDAQ: ... the United States Patent and Trademark Office (USPTO) has issued ... Peripheral Artery Disease." The patent claims cover the biomarker alpha1beta ... diagnosis of PAD. "This will be our ...
... 1, 2011 International Isotopes Inc. (OTC Bulletin Board: ... under both ISO-9001 and ISO-13485 standards for the manufacture ... cobalt-60 products. "ISO" is the International Organization ... promulgates worldwide commercial quality standards for manufacture of a ...
Cached Biology Technology:Medical Malpractice Insurance Company- Healthcare Providers Insurance Exchange (HPIX) has Expanded its Presence in New Jersey, Opens New Office 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 2Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent 3International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices 2International Isotopes Inc. Announces Successful International Standards Certification for Manufacture of Its Nuclear Medicine Products and Devices 3
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/26/2015)... The Granite Club, Canada,s ... announced it has implemented a state-of-the-art access and security ... and staff, while restricting access to authorized users only. ... IMID Access system because it has the perfect combination ... in addition to unparalleled security," said James DiRenzo ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... tends to conjure up images of tropical vacations, complete ... Rapid climate change, and increased pollution, ocean acidification ... factors heavily stress corals, and thus put both the ... and shelter, and the $1 billion dollar tourism industry ...
... cell, little bubbles called vesicles serve as container ships, ... cell membrane. Some of these vesicles, called post-Golgi vesicles, ... Scientists have long believed that other, similar vesicles handle ... an independent process. By using a finely honed type ...
... Researchers studying the nervous control of nematode mating behavior ... to mate with a hermaphrodite. Writing in the open ... Paul Sternberg from the California Institute of Technology investigated ... tail muscles to achieve an exploratory embrace. ...
Cached Biology News:Cells use import machinery to export their goods as well 2Cells use import machinery to export their goods as well 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... Provides a fast and easy method ... mitochondrial fraction from mammalian tissues. Most ... inner and outer membranes. The kit ... studies and proteome profiling. Also included ...
Sufficient reagents for 50 applications.Mitochondria Isolation Kit Reagent A, 50 ml Mitochondria Isolation Kit Reagent B, 500 l Mitochondria Isolation Kit Reagent C, 70 ml...
Biology Products: